Duloxetine Capsule, Delayed Release
Product Images NDC 43547-381

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 43547-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

26313df6-figure-09 (20 mg 30 Capsule)

Label for Duloxetine delayed-release capsules, USP, 20 mg strength, by Solco Healthcare US, LLC. The label indicates each capsule contains 22.4 mg duloxetine hydrochloride equivalent to 20 mg duloxetine. The package contains 30 capsules. Storage instructions and manufacturer information, Zhejiang Huahai Pharmaceutical Co., Ltd in China, are included along with cautionary notes and an image of the pink and white capsule.*

FDA Label Image

26313df6-figure-10 (30mg 30 Capsules)

Duloxetine Delayed-Release Capsules, USP 30 mg by Solco Healthcare US, LLC. The label shows a blue and white capsule package containing 30 capsules. It includes the NDC 43547-380-03, directions to dispense accompanying medication guide, storage instructions, and manufacturer information Zhejiang Huahai Pharmaceutical Co., Ltd. The label indicates Rx only and highlights the 30 mg strength.*

FDA Label Image

26313df6-figure-11 (60 mg 30 Capsule)

Duloxetine 60 mg delayed-release capsules label from Solco Healthcare US, LLC. The label states each capsule contains 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine. The package contains 30 capsules and includes storage instructions and a note to dispense accompanying medication guide. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., China.*

FDA Label Image

Image 01

A line graph depicting the proportion of patients with relapse over time for two treatment groups: Duloxetine and placebo. The x-axis represents time, and the y-axis shows the proportion of patients with relapse. Two lines compare relapse rates, with Duloxetine showing a lower proportion than placebo throughout the observed period.*

FDA Label Image

Image 02

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) following randomization in a clinical study. The graph shows two treatment groups: placebo and duloxetine, with duloxetine having a lower proportion of relapse over approximately 250 days.*

FDA Label Image

Image 03

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline for duloxetine at doses 60 mg BID, 60 mg QD, 20 mg QD, and placebo. Each treatment group is represented by a distinct line pattern and markers illustrating the comparative efficacy in pain improvement.*

FDA Label Image

Image 04

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, once daily, and placebo. The graph compares efficacy over a range of pain improvement percentages, with Duloxetine groups showing higher patient improvement rates than placebo.*

FDA Label Image

Image 05

A line graph comparing percent improvement in pain from baseline with Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo groups. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. The graph shows higher patient improvement percentages for Duloxetine groups compared to placebo across the range.*

FDA Label Image

Image 06

A line graph depicting the percentage of patients who improved with varying percent improvement in pain from baseline. The graph compares Duloxetine at 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo groups. The y-axis shows the percentage of patients improved, and the x-axis shows the percent improvement in pain from baseline.*

FDA Label Image

Image 07

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. The graph includes two lines, one for each treatment group, showing patient response trends over increasing pain improvement thresholds.*

FDA Label Image

Image 08

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) over increasing percent improvement thresholds for placebo and duloxetine 60 mg once daily. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines illustrate patients' response rates to placebo and duloxetine treatment across different improvement levels.*

FDA Label Image

Image 09

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo groups. Duloxetine shows higher patient improvement percentages at most pain improvement thresholds.*

FDA Label Image

C:\users\ra\desktop\duloxetine-spl\molecular.jpg (Structure)

Chemical structure of duloxetine hydrochloride, shown with its bicyclic aromatic ring system, thiophene ring, and secondary amine with methyl substitution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.